Hints and tips:
...Myers Squibb; and a Novartis drug to treat heart failure called Entresto....
...Bristol-Myers Squibb has agreed to acquire Turning Point Therapeutics for $4.1bn in the latest in a series of bolt-on acquisitions by pharmaceutical companies looking to bolster their drug pipelines....
...Merck, Bristol Myers Squibb and Amgen have all used these aggressive tactics to protect blockbuster drugs from competition, said O’Reilly....
...Last year, US drugmaker Bristol Myers Squibb said it could divert investment away from the UK because of the increasing clawbacks....
...A coalition of ethical investors have asked Johnson & Johnson, Merck, Pfizer, Eli Lilly, Gilead, Amgen, Regeneron, Bristol Myers Squibb and AbbVie to publish a report on the process they follow when applying...
...SeaGen also recently signed a partnership with French drugmaker Sanofi and has agreements with Takeda and Bristol Myers Squibb among others. SeaGen declined to comment....
...It exited its position in generic drugs maker Teva and sold more than 70 per cent of its remaining shares in AbbVie and Bristol-Myers Squibb....
...Even though its balance sheet is smaller than rivals such as JPMorgan and Bank of America, it has tapped its relationship with Japan’s Mitsubishi UFJ to finance huge loans before, including $33.5bn for Bristol-Myers...
...The company markets Reblozyl, a drug that treats anaemia in certain blood disorders, in the US, Europe and Canada in collaboration with Bristol-Myers Squibb, which owns an 11.5 per cent stake in Acceleron...
...J&J shares trade on a multiple of 18 times forward earnings, well above Pfizer’s 12 times and Bristol-Myers Squibb’s 9 times. Duato will have to deliver on the vaccine front to justify this premium....
...Pfizer, AbbVie and Bristol-Myers Squibb all have blockbuster drugs due to lose exclusivity soon and have recently sealed multibillion-dollar deals....
...Berkshire reduced its stakes in drugmakers including Merck, Bristol-Myers Squibb and AbbVie in the first quarter, cut more than half of its holding in oil major Chevron, and sold the entirety of its positions...
...It increased its stakes in AbbVie, Bristol-Myers Squibb and Merck, but sold out of Pfizer....
...The chief executive of Bristol-Myers Squibb described the US government’s support for waiver as “very concerning” during an interview at the FT US Pharma and Biotech Summit on Thursday....
...Berkshire added 21.3m shares of AbbVie, 30m shares of Bristol-Myers Squibb, 22.4m shares of Merck and 3.7m shares of Pfizer to its $245bn equity portfolio, according to a filing with the US securities regulator...
...(Bloomberg) News round-up Bristol-Myers Squibb to buy heart treatment maker for $13.1bn (FT + Lex) France’s Engie sells €3.4bn stake in Suez (FT) HPS raises $9bn as investors race into direct lending...
...Other deals included Bristol-Myers-Squibb’s $74bn takeover of biotech group Celgene and Pfizer’s $11.4bn acquisition of Array BioPharma....
...Shares in Bristol-Myers Squibb jumped 4.2 per cent to $48.52 in morning trading in New York, while Amgen stock rose 2.2 per cent to $203.42....
...Early last year Bristol-Myers Squibb purchased Celgene for $93bn, while Pfizer snapped up Array BioPharma for $11bn in June....
...Filings with the Securities and Exchange Commission show Renaissance owned almost 4m Tesla shares at the end of last year, making the Elon Musk company its second-largest holding behind Bristol-Myers Squibb...
...While those takeovers do not generate the same fanfare as marquee transactions such as Bristol-Myers Squibb’s $93.4bn takeover of rival drugmaker Celgene, they are critical fee generators for advisers....
...drug price increases at the start of the year included a 7.4 per cent rise in the price of Humira, AbbVie’s blockbuster drug for treating inflammatory diseases, and a 6 per cent increase in the price of Bristol-Myers...
...A chart to start the year with: corporate fee payers Bristol-Myers Squibb’s $93bn takeover of rival drugmaker Celgene was one of the first megadeals out of the gate last year, and it proved incredibly lucrative...
...The bank nonetheless enjoyed a blockbuster payday for its work advising Bristol-Myers Squibb on its takeover of Celgene, a deal that generated Morgan Stanley an $82m advisory fee JPMorgan Chase reported...
...Earlier this year, Bristol-Myers Squibb acquired fading biotech star Celgene while promising a massive near-term boost in profits per share....
International Edition